Resonance Health Limited (ASX: RHT) delivered a solid FY26 result, reflecting improved performance across its medical imaging, clinical research and investigator-site businesses. Revenue climbed 42% year-on-year to AU$15.8 million, while normalised operating EBITDA increased 83% to AU$2.6 million. Improved cost efficiency lifted the EBITDA margin to 16%, compared with 13% in FY25. The company also returned to profitability, generating statutory net profit after tax of AU$1.5 million, reversing the AU$1.7 million loss recorded a year earlier.Cash generation strengthened alongside earnings, with free cash flow reaching AU$2.8 million, representing growth of 148%. Net operating cash flow increased to AU$2.9 million, while year-end cash stood at AU$4.8 million and net cash reached AU$2.3 million. Looking ahead, growth visibility is supported by a SaMD order and tender pipeline exceeding AU$12 million, continuing clinical-trial revenue and expanding demand for metabolic and liver-related diagnostic solutions. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au